

Anti-CD74 Antibody (Milatuzumab)

Introduction

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74 is an integral membrane protein involved in promoting B-cell growth and survival. Milatuzumab causes the generation of free radical oxygen species and loss of mitochondrial membrane potential. Milatuzumab also reduces CD20/CD74 aggregates and cell adhesion, leading to cell death.

Product parameters

Alternative Names	MEDI-115, hLL1, IMMU-115
Target Accession	P04233
Target	CD74
CAS number	899796-83-9
Molecular Weight	145.66 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CD74 Fc at 2 ug/mL can bind Anti-CD74 Antibody (Milatuzumab), EC50=0.04337 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

